Rethinking Acute SVT Management Podcast-Rethinking Acute SVT Management Video

Rethinking Acute SVT Management Video

Video Transcription

Video Summary

Dr. Kamala Tamarisa discusses etripamil, a short-acting intranasal L-type calcium-channel blocker intended for at-home treatment of acute SVT. The described dose is 70 mg total, with one repeat after 10 minutes if needed, up to 140 mg in 24 hours. Trial participants reported nasal congestion, discomfort, or mild bleeding; it should be avoided in pre-excited AF, significant bradycardia, sinus-node dysfunction, high-grade AV block, and pregnancy. AF treatment is still under study. For stable SVT during pregnancy, options include metoprolol, verapamil, or adenosine; recurrent cases may be treated with ablation or medication.

Keywords

etripamil

acute SVT

intranasal calcium-channel blocker

pregnancy SVT treatment

arrhythmia contraindications